New data from LivaNova has demonstrated the clinical benefit of its programming algorithm in patients with obstructive sleep apnoea (OSA). Trial data demonstrated that the company's PolySync ...
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results